KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Accumulated Expenses (2018 - 2019)

Arbutus Biopharma (ABUS) has disclosed Accumulated Expenses for 5 consecutive years, with $137000.0 as the latest value for Q4 2019.

  • Quarterly Accumulated Expenses fell 89.71% to $137000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $137000.0 through Dec 2019, down 89.71% year-over-year, with the annual reading at $137000.0 for FY2019, 89.71% down from the prior year.
  • Accumulated Expenses hit $137000.0 in Q4 2019 for Arbutus Biopharma, down from $203000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.3 million in Q4 2018 to a low of $28000.0 in Q1 2015.
  • Historically, Accumulated Expenses has averaged $558250.0 across 3 years, with a median of $416500.0 in 2015.
  • Biggest YoY gain for Accumulated Expenses was 36.19% in 2015; the steepest drop was 97.97% in 2015.
  • Year by year, Accumulated Expenses stood at $952000.0 in 2015, then surged by 39.81% to $1.3 million in 2018, then crashed by 89.71% to $137000.0 in 2019.
  • Business Quant data shows Accumulated Expenses for ABUS at $137000.0 in Q4 2019, $203000.0 in Q3 2019, and $342000.0 in Q2 2019.